ctDNA Molecular Response based on breast cancer driver mutations predicts progression in aromatase inhibitor-sensitive first line treatment of oestrogen receptor-positive (ER+) HER2-negative (HER2-) advanced breast cancer

被引：1
|
作者：
Bailleux, Caroline
Bachelot, Thomas
Bidard, Francois-Clement
Hardy-Bessard, Anne-Claire
Bieche, Ivan
Pradines, Anne
Clatot, Florian
Rouge, Thibault De La Motte
Canon, Jean-Luc
Pistilli, Barbara
Chang, Kyle
Quinn, Katie J.
Gustafson, Heather L.
Dalenc, Florence
Foa, Cyril
Ammarguellat, Hanifa
Bernard-Marty, Chantal
Lucas, Brigitte
Barthier, Sophie
Lorchel, Fabrice
Gisserot, Olivier
Arnould, Laurent
Mauduit, Marjorie
Lemonnier, Jerome
Berger, Frederique
Delaloge, Suzette
Andre, Fabrice
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-PD17-02
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD17-02
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Imlunestrant monotherapy and in combination with abemaciclib, with or without an aromatase inhibitor, in estrogen receptor-positive (ER+), HER2-negative (HER2-) advanced breast cancer (aBC): updated results from the EMBER study
    Jhaveri, Komal
    Lim, Elgene
    Jeselsohn, Rinath
    Ma, Cynthia
    Hamilton, Erika
    Osborne, Cynthia
    Bhave, Manali
    Kaufman, Peter
    Beck, J. Thaddeus
    Manso, Luis
    Parajuli, Ritesh
    Wang, Hwei-Chung
    Tao, Jessica
    Dhakal, Ajay
    Pierga, Jean-Yves
    Lu, Yen-Shen
    Larson, Tim
    Gilarranz, Yolanda Jerez
    Ismail-Khan, Roohi
    Bacchion, Francesca
    Karacsonyi, Claudia
    Li, Yujia
    Estrem, Shawn T.
    Nguyen, Bastien
    Beeram, Muralidhar
    CANCER RESEARCH, 2024, 84 (09)
  • [2] Ribociclib for the treatment of advanced hormone receptor-positive, HER2-negative breast cancer
    Lopez-Tarruella, Sara
    Jerez, Yolanda
    Marquez-Rodas, Ivan
    Echavarria, Isabel
    Martin, Miguel
    FUTURE ONCOLOGY, 2017, 13 (24) : 2137 - 2149
  • [3] A novel scoring system based on the clinical and genomic variables to predict the early relapse in estrogen receptor-positive/HER2-negative (ER+/HER2-) breast cancer
    Lin, Caijin
    Wu, Jiayi
    Ding, Shuning
    Andriani, Lisa
    Chen, Weilin
    Liu, Deyue
    Zhu, Li
    CANCER RESEARCH, 2020, 80 (04)
  • [4] Molecular classification of hormone receptor-positive HER2-negative breast cancer
    Jin, Xi
    Zhou, Yi-Fan
    Ma, Ding
    Zhao, Shen
    Lin, Cai-Jin
    Xiao, Yi
    Fu, Tong
    Liu, Cheng-Lin
    Chen, Yi-Yu
    Xiao, Wen-Xuan
    Liu, Ya-Qing
    Chen, Qing-Wang
    Yu, Ying
    Shi, Le-Ming
    Shi, Jin-Xiu
    Huang, Wei
    Robertson, John F. R.
    Jiang, Yi-Zhou
    Shao, Zhi-Ming
    NATURE GENETICS, 2023, 55 (10) : 1696 - +
  • [5] Molecular classification of hormone receptor-positive HER2-negative breast cancer
    Xi Jin
    Yi-Fan Zhou
    Ding Ma
    Shen Zhao
    Cai-Jin Lin
    Yi Xiao
    Tong Fu
    Cheng-Lin Liu
    Yi-Yu Chen
    Wen-Xuan Xiao
    Ya-Qing Liu
    Qing-Wang Chen
    Ying Yu
    Le-Ming Shi
    Jin-Xiu Shi
    Wei Huang
    John F. R. Robertson
    Yi-Zhou Jiang
    Zhi-Ming Shao
    Nature Genetics, 2023, 55 : 1696 - 1708
  • [6] Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
    Ditsch, Nina
    Schmidt, Marcus
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2019, 79 (12) : 1328 - 1335
  • [7] Sapanisertib plus Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive/HER2-Negative Advanced Breast Cancer after Progression on Aromatase Inhibitor
    Garcia-Saenz, Jose A.
    Martinez-Janez, Noelia
    Cubedo, Ricardo
    Jerez, Yolanda
    Lahuerta, Ainhara
    Gonzalez-Santiago, Santiago
    Ferrer, Nieves
    Ramos, Manuel
    Alonso-Romero, Jose L.
    Anton, Antonio
    Carrasco, Eva
    Chen, Jingjing
    Neuwirth, Rachel
    Galinsky, Kevin
    Vincent, Sylvie
    Leonard, E. Jane
    Slamon, Dennis
    CLINICAL CANCER RESEARCH, 2022, 28 (06) : 1107 - 1116
  • [8] Characteristics of patients (pts) with previously treated, oestrogen receptor-positive, HER2-negative advanced breast cancer (ER+, HER2-aBC) who had rapid progression (RP) in acelERA BC
    Martin Jimenez, M.
    Hilz, S.
    Collier, A.
    Chibly, A.
    Sohn, J.
    Bardia, A.
    Lim, E.
    Mac Gregor, M. Chavez
    Martinalbo, J.
    Perez-Moreno, P. D.
    Moore, H. M.
    ANNALS OF ONCOLOGY, 2023, 34 : S356 - S357
  • [9] Immunotherapy for hormone receptor-positive HER2-negative breast cancer
    Cardoso, Fatima
    Hirshfield, Kim M.
    Kraynyak, Kimberly A.
    Tryfonidis, Konstantinos
    Bardia, Aditya
    NPJ BREAST CANCER, 2024, 10 (01)
  • [10] Sacituzumab govitecan for hormone receptor-positive HER2-negative advanced breast cancer
    Garrigos, Laia
    Camacho, Daniela
    Perez-Garcia, Jose Manuel
    Llombart-Cussac, Antonio
    Cortes, Javier
    Antonarelli, Gabriele
    EXPERT REVIEW OF ANTICANCER THERAPY, 2024, 24 (10) : 949 - 958
12345